Skip to content

Computer-assisted Fetal Monitoring - Cardiology

Computer-assisted Fetal Monitoring - Cardiology

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04235075
Acronym
SURFAO-CARDIO
Enrollment
20
Registered
2020-01-21
Start date
2020-08-31
Completion date
2022-10-31
Last updated
2020-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

Signal Database, Pregnancy, Electrocardiogram, Usability, Multimodal signal acquisition

Brief summary

In the context of fetal heart monitoring (prenatal and during childbirth), the SurFAO project offers an alternative to current clinical routines. The challenge is to extract, from non-invasive sensors on the maternal abdomen, a fetal electrocardiogram (ECGf) of great quality allowing a clinical diagnosis (follow-up of the FHR (Fetal Heart Rate)) and extraction of ECG waveforms). The approach proposes a technological breakthrough shared by a consortium of researchers and clinicians. The originality is driven by innovative methodological choices: the use of a multimodal system (ECG coupling with PCG (phonocardiography)) for the signal acquisition in order to increase the robustness of information extraction, by taking into account clinical uses and the need to support the monitoring process, and by setting up a multimodal database. The objective is to feed a database that will be used in the future to develop ECGf extraction methods.

Detailed description

To monitor the well-being of a fetus or for clinical diagnosis, the challenge is to extract a high-quality fetal electrocardiogram (fECG) signal from non-invasive sensors on the maternal abdomen. As early as the 20th week of amenorrhea, heart rhythm disorders (tachycardia, bradycardia) can be detected in the fetus, most often by fortuitous circumstance, during routine obstetrical ultrasound examinations. It is then necessary to analyze these rhythmic anomalies, understand their origin and, if necessary, initiate pharmacotherapy. The effectiveness of the treatments is then monitored by ultrasound in the high-risk pregnancy department. The analysis of a fetal electrocardiogram (fECG) provides information that allows to determine the nature of the rhythm disorder, its origin and therefore its potential severity. The innovative methodological approach considered for the extraction of non-invasive ECGf is to combine 2 complementary modalities of the same cardiac phenomenon. This is achieved by combining the use of ECG sensors with sound sensors giving access to phonocardiographic signals (PCG).

Interventions

DEVICEECG/PCG and ultrasound signal acquisition

The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes. The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants.

Sponsors

TIMC-IMAG
CollaboratorOTHER
University Grenoble Alps
CollaboratorOTHER
Clinical Investigation Centre for Innovative Technology Network
CollaboratorNETWORK
University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Creation of a multimodal database

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* single pregnancy * between 20 and 26 weeks of amenorrhea * with a BMI between 18.5 and 30 at the beginning of pregnancy * fetal heart considered normal after expert ultrasound * examination conditions deemed correct by the expert * registered in a social security scheme * having signed the study consent form

Exclusion criteria

* subject to a legal protection measure or unable to express consent (guardianship, guardianship) (article L1121-8) * deprived of liberty by judicial or administrative decision (article L1121-6) * in a period of exclusion from another study * with toxic consumption (i.e. tobacco, alcohol, cannabis) * Intrauterine growth retardation (estimated fetal weight less than the 10th percentile) * fetal heart rhythm disorders * with unclear pregnancy term * with pregnancy denial

Design outcomes

Primary

MeasureTime frameDescription
ECG / PCG Signals database20 minutesSynchronized signals from ECG electrodes and PCG sensors. Signals will be processed to extract fetal ECG and specific waveforms characteristics of fECG (in parts of R waves, P waves, QT intervals, ST intervals).
Ultrasound signals database10 minutesThe fetal heart activity is analyzed using mechanograms and Doppler during ultrasound (gold standard).

Secondary

MeasureTime frameDescription
Subject acceptability : Score10 minutesThe subject acceptability score will be composed by the addition of 7 scales. These scales have been specifically created for the SurFAO system. The score can go from 0 (worst) to 70 (best). Each scale can give from 0 to 10 points to the final score.
Subject Acceptability : Descriptive analysis10 minutesOpen questions will be asked to the subjects in a questionnaire. A descriptive analysis will be done with the answers.
Use Error evaluation : System Usability Scale (SUS)10 minutesThe System Usability Scale (SUS) is a validated tool for assessing the subjective usability of a system, in this case, the SurFAO System. It contains 10 questions that are rated on a scale from 1 to 5. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Jeff Sauro established the average score of SUS is 68. The score can go from 0 (worst) to 100 (best).
Use Error evaluation : Descriptive analysis60 minutesDifficulties in using the system will be recorded in the case report form and identified using photographs and video. A descriptive analysis will be done.

Countries

France

Contacts

Primary ContactMatthias LACHAUD, MD
MLachaud@chu-grenoble.fr+33 4 76 76 94 95
Backup ContactIsabelle Boudry, PhD
IBoudry@chu-grenoble.fr+33 4 76 76 66 45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026